Recruiting OBSERVATIONAL NCT05481437

A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma

Specified Drug Use Surveillance for ADCETRIS Intravenous Infusion 50 mg -Untreated CD30 Positive Hodgkin Lymphoma (Pediatric)

Sponsor: Takeda

Conditions Hodgkin Lymphoma

Interventions Brentuximab Vedotin

Updated 6 times since 2022 Last updated: Apr 15, 2025 Started: Aug 1, 2022 Primary completion: Jul 31, 2027 Completion: Jul 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05481437, this observational or N/A phase trial focuses on Hodgkin Lymphoma and remains actively recruiting participants. Sponsored by Takeda, it has been updated 6 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

May 2025 — Present [monthly]

Recruiting
Sep 2024 — May 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Jan 2024 — Jul 2024 [monthly]

Recruiting
Oct 2023 — Jan 2024 [monthly]

Recruiting

▶ Show 1 earlier version

Sep 2022 — Oct 2023 [monthly]

Recruiting

First recorded

Aug 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan